鄰近類別 圖書 [1/1] 期刊論文 [327/330] 類別統計 近3年內發表的文件:16(8.94%) 含全文筆數:115(64.25%) 文件下載次數統計 下載大於0次:115(100.00%) 下載大於100次:112(97.39%) 檔案下載總次數:39303(22.07%) 最後更新時間: 2024-12-01 07:53 上傳排行 資料載入中..... 下載排行 資料載入中..... 最近上傳 Single-cell RNA sequencing via Endo... Nivolumab plus ipilimumab (N plus I... Risk of type 2 diabetes mellitus an... Phase 1 studies of D07001-F4 and D0... Updated overall survival (OS) from ... Outcomes of post-immunotherapy dura... Updated overall survival (OS) from ... Updated results of the FOENIX-CCA2 ... Comparative genomic analysis and it... A phase II trial of nivolumab, gemc...

跳至: (選擇年份) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (選擇月份) January February March April May June July August September October November December 或輸入年份:

由新到舊排序 由最舊的開始

顯示項目1-25 / 179. (共8頁) 1 2 3 4 5 6 7 8 > >> 每頁顯示[10|25|50]項目

日期	題名	關聯
2023-11	Nivolumab plus ipilimumab (N plus I) for potentially resectable hepatocellular carcinoma (HCC): Efficacy and surgical outcome	Annals of Oncology. 2023 Nov;34(Suppl. 3):S1390.
2023-11	Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis	Annals of Oncology. 2023 Nov;34(Suppl. 4):S1536-S1537.
2023-10	Risk of type 2 diabetes mellitus and hyperlipidemia in patients with chronic myeloid leukemia initiating tyrosine kinase inhibitors: A nationwide cohort study	Pharmacoepidemiology and Drug Safety. 2023 Oct;32(Suppl. S1):575.
2023-06	Phase 1 studies of D07001-F4 and D07001-softgel capsule: Oral metronomic gemcitabine in subjects with advanced solid tumors	Journal of Clinical Oncology. 2023 Jun;41(16, Suppl.):Meeting Abstract 3148.
2022-11	Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC)	Annals of Oncology. 2022 Nov;33(Suppl. 9):S1462-S1463.
2022-10	Outcomes of post-immunotherapy durable responders of advanced hepatocellular carcinoma - with emphasis on locoregional therapy for oligoprogression	Hepatology. 2022 Oct;76(Suppl.1):S1411-S1412.
2022-09	Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC)	Annals of Oncology. 2022 Sep;33(7):S565-S566.
2022-07	Toward collaboration among cancer trials groups in Asia: TCOG perspective	Annals of Oncology. 2022 Jul;33(Suppl. 6):S449.
2022-07	Improved survival with neoadjuvant chemotherapy in stage III pancreatic cancer: A single institutional experience	Annals of Oncology. 2022 Jul;33(Suppl. 6):S535.
2022-07	A phase II trial of nivolumab, gemcitabine and S-1 as the frst-line treatment in patients with biliary tract cancer	Annals of Oncology. 2022 Jul;33(Suppl. 6):S478.
2022-07	Potential roles of gut microbiome in patients with hepatocellular carcinoma treated with immune checkpoint inhibitors	Annals of Oncology. 2022 Jul;33(Suppl. 6):S484.
2022-06	Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements	Journal of Clinical Oncology. 2022 Jun;40(16, Suppl.):Abstract number 4009.
2022-06	Comparative genomic analysis and its prognostic impact on survival between viral hepatitis-related and non-viral hepatitis intrahepatic cholangiocarcinoma	Journal of Clinical Oncology. 2022 Jun;40(16, Suppl.):Abstract number 4120.
2022-02-01	A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1	Journal of Clinical Oncology. 2022 Feb 01;40(4, Suppl.):378.
2022-02-01	A prospective phase II study of biweekly S-1, leucovorin and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma	Journal of Clinical Oncology. 2022 Feb 01;40(4, Suppl.):550.
2022-02	Phase 1 study of nanoliposomal irinotecan in combination with trifluridine/tipiracil in refractory solid tumors	Journal of Clinical Oncology. 2022 Feb;40(4, Suppl.):660.
2021-09	INTEGRATE IIb: A randomised phase III open label study of regorafenib plus nivolumab vs standard chemotherapy in refractory advanced gastro-oesophageal cancer (AGOC)	Annals of Oncology. 2021 Sep;32(Suppl. 5):S1074.
2021-09	A phase II trial of nivolumab and gemcitabine and S-1 as the first-line treatment in patients with advanced biliary tract cancer	Annals of Oncology. 2021 Sep;32(Suppl. 5):S377.
2021-09	Primary results of phase 2 FOENIX-CCA2: the irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements	Oncology Research and Treatment. 2021 Sep;44(Suppl. 2):222.
2021-07	Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements	Cancer Research. 2021 Jul;81(13, Suppl.):Abstract number CT010.
2021-05	Phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC)	Journal of Clinical Oncology. 2021 May;39(15, Suppl.):Abstract number 4090.
2021-05	TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma	Journal of Clinical Oncology. 2021 May;39(15, Suppl.):4143.
2021-05	A phase 2 study of liposomal irinotecan with 5-fluorouracil and leucovorin in squamous cell carcinoma of head and neck or esophagus after prior platinum-based chemotherapy or chemoradiotherapy	Journal of Clinical Oncology. 2021 May;39(15, Suppl.):Abstract number 6025.
2020-09	Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in patients with pretreated biliary tract cancer	Annals of Oncology. 2020 Sep;31(Suppl. 4):S268-S269.
2020-09	Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study	Annals of Oncology. 2020 Sep;31(Suppl. 4):S1192.

顯示項目1-25 / 179. (共8頁) 1 2 3 4 5 6 7 8 > >> 每頁顯示[10|25|50]項目